What the table does not capture is the qualitative experience of each medication
Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
If I had lost almost no weight, just to have my brain working the way its working, I would stay on this medication forever. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing
This condition, non-arteritic anterior ischemic optic neuropathy (NAION) can be permanent, and there are not effective treatments for the condition
Loti Labs ships same day for orders placed before 1pm EST Monday through Friday
Due to a similar model fit, random effects models were chosen over fixed effects models for all outcomes